drugset / Trial / NCT00740064

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

NCT00740064

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Raltegravir and Epzicom over 48 weeks in ART-naive HIV-infected subjects.

Timeline

Start
2008-05
Primary completion
2009-08
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir/Lamivudine Unknown
Subject Raltegravir Other / unclassified 400 mg